Find Clinical Trials

Inclusion Criteria: 1. Hong Kong residents aged 18-65 years; 2. Able to read Chinese and type in Chinese or English; 3. Have a Patient Health Questionnaire-9 (PHQ-9) score of 10 or higher, indicating at least a moderate level of depressive symptoms; 4. Meet the Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnostic criteria for current MDD according to the Mini International Neuropsychiatric Interview (MINI); 5. Have a Mediterranean Diet Index (KIDMED 2.0) score less than 3, indicating very-low-quality diet; 6. Possess an Internet-enabled iOS- or Android-operated mobile device; and 7. Willing to provide informed consent and comply with the trial protocol. Exclusion Criteria: 1. The presence of other current psychiatric disorders as assessed by the MINI (bipolar disorder, posttraumatic stress disorder, personality disorders, eating disorders, psychotic disorders, or substance abuse disorder); 2. Have a medical condition or neurocognitive disorder that may prevent dietary changes as recommended by physicians or dietitians; 3. Current serious suicidal risk (non-fleeting intent or plan) as assessed by a PHQ-9 Item 9 score \>2 (referral information to professional mental health services will be provided); 4. Involvement in dietary changes (self-initiated/supervised by professionals) in the past 2 weeks; 5. Involvement in any psychological treatment specifically for depression in the past 6 months; 6. A change in medication within 2 weeks prior to the baseline assessment/during the study; 7. Pregnancy and hospitalization; 8. Current participation in any other trial(s); and 9. Unwilling to change their diet if being allocated to the MediDiet group or food allergies or intolerances preventing diet adherence (specifically allergies to seafood, soy, nuts, yogurt, or dairy products).

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Age ≥ 18 years at the time of signing informed consent 4. Expected survival ≥ 3 months in the judgment of the investigator 5. ECOG PS 0-1 6. Adequate Organ Function per the following criteria (within 10 days of study registration): * Absolute lymphocyte count ≥ 400/mm3 * Absolute neutrophil count ≥ 1000/mm3 * Platelets ≥ 75,000/mm3 * Hemoglobin ≥ 9g/dL * Serum creatinine \< 2.0 mg/dL OR measured or calculated creatinine clearance ≥ 50 ml/mm * Total bilirubin ≤ mg/dL * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) \< 5.0 times normal 7. Agreement to adhere to Lifestyle Considerations throughout study duration 8. A diagnosis of either of the following: a. Prostate Cancer: i. Histological and/or cytological confirmation of prostate adenocarcinoma. ii. Participants must have progressive mCRPC at screening iii. Serum testosterone levels \<50 ng/dL during screening. iv. Must have progressed on at least one prior ARPI (abiraterone acetate, enzalutamide, apalutamide, or darolutamide). v. Participants must have ≥1 metastatic lesion that is present on baseline CT, MRI, or bone scan obtained ≤28 days prior to registration. b. Breast Cancer i. Histological and/or cytological confirmation of invasive breast cancer. ii. Participants must have previously treated metastatic breast cancer at screening. Metastatic breast cancer must be evaluable by RECIST 1.1 criteria. iii. Must have progressed on at least two prior endocrine or targeted therapies or at least two lines of cytotoxic chemotherapy. If HER2 positive, then must have progressed on or been intolerant of at least one HER2 targeted therapy. iv. Participants must have ≥1 metastatic lesion that is present on baseline CT, MRI, or bone scan obtained ≤28 days prior to registration. Exclusion Criteria: 1. Pregnancy (must have negative pregnancy test within 7 days prior to study registration) or lactation 2. History of a recent myocardial infarction (within one year) or a past myocardial infarction (more than one year prior to enrollment) who are actively requiring nitroglycerine more than once per week 3. Inadequate cardiac function, as defined as any of the following: * Uncontrolled angina or severe ventricular arrhythmias * Clinically significant pericardial disease * History of myocardial infarction (MI) in the last year before registration * Class 3 or higher New York Heart Association Congestive Heart Failure 4. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 5. Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to registration 6. Active liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis 7. Is HIV positive or has evidence of active Hepatitis C virus or active Hepatitis B virus. 8. Active bleeding or a pathological condition that is associated with a high risk of bleeding (therapeutic anticoagulation is allowed) 9. Has an active infection requiring systemic therapy 10. A serious uncontrolled medical disorder that in the opinion of the Investigator may be jeopardized by the treatment with protocol therapy 11. Has a known history of active TB (Bacillus Tuberculosis) 12. Has received a live vaccine within 30 days of study registration. 13. Treatment with any investigational agent within 3 weeks prior to study registration 14. Active second malignancy requiring systemic treatment. Exceptions include basal cell carcinoma of the skin, treated cervical cancer, and squamous cell carcinoma of the skin 15. Has active autoimmune disease that has required systemic treatment in the 2 years prior to registration (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator. 17. Patient may be excluded if, in the opinion of the PI and investigator team, the patient is not capable of being compliant Additional Exclusion Criteria for Patients with Prostate Cancer: 1. Has small cell neuroendocrine carcinoma (pure or mixed) on prior or current histologic evaluation of primary or metastatic lesions 2. Has an actionable BRCA1 or BRCA2 alteration, for which approved therapies are available, e.g., PARP inhibitors, unless these therapies are not appropriate for the participant as determined by the investigator or the participant refuses such therapy. Participants with one of these mutations and who have progressed on targeted therapy are eligible. Additional Exclusion Criteria for Patients with Breast Cancer: 1. Has an actionable BRCA1 or BRCA2 alteration, for which approved therapies are available, e.g., PARP inhibitors, unless these therapies are not appropriate for the participant as determined by the investigator or the participant refuses such therapy. Participants with one of these mutations and who have progressed on targeted therapy are eligible. 2. Participants in visceral crisis at risk of immediately life-threatening complications in the short term, including participants with massive uncontrolled effusions (pleural, pericardial, and peritoneal), pulmonary lymphangitis, or liver involvement \> 50%.

Inclusion Criteria: * Age ≥ 18 years * Clinical indication for transjugular intrahepatic portosystemic shunt (TIPS) creation according to standard clinical practice (e.g., refractory ascites or variceal bleeding) * Ability to provide written informed consent Exclusion Criteria: * Inability or unwillingness to provide informed consent * Pregnancy or breastfeeding * Absolute contraindications to TIPS according to current clinical standards (e.g., severe right heart failure, uncontrolled systemic infection) * Participation in another clinical study that may interfere with the results of this study

Inclusion Criteria: * Adults and adolescents \>=12 years of age, at the time of signing the informed consent/assent. For countries where local regulations or the regulatory status of study medication permit enrolment of adults only, participants recruited will be \>=18 years of age. * Participants must have a documented physician diagnosis of asthma for \>=2 years that meets the National Heart, Lung, and Blood Institute, National Institute for Health and Care Excellence or Global Initiative for Asthma guidelines * Have previously confirmed history of at least 2 exacerbations over the last 3 years prior to screening, with at least 1 of those exacerbations occurring in the previous year prior to Screening Visit 1. * Exacerbation requiring treatment with systemic Corticosteroid (CS), for at least 3 days, despite the use of low to medium dose Inhaled corticosteroids (ICS)/ Long-acting beta2-adrenergic receptor agonist (LABA). * A well-documented requirement for treatment with low to medium dose ICS/LABA (in the 12 months prior to screening visit. Treatment should be stable for 3 months prior to screening. If participants are taking Maintenance and Reliever Therapy/Single Maintenance and Reliever Therapy regularly, the total daily dose should be incorporated into the assessment of low or medium dose ICS. * Study will limit enrolment to a maximum of 40 percent (%) of participants on low dose ICS/LABA. * Sex and Contraceptive/Barrier Requirements Male or eligible female Participants: * Male Participants: Contraception for male participants with female partners is not required. * Female Participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: * Is a participant of nonchildbearing potential (PONCBP) OR * Is a participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (\<)1%, from at least 14 days prior to the first dose of study intervention until at least 35 weeks after the last administered dose of study intervention. * A POCBP must have a negative highly sensitive serum pregnancy test at Screening Visit 1, Exit Visit 11 or Withdrawn from study visit, and a negative highly sensitive urine pregnancy test within 24 hours before the first dose of study intervention. * Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated in relationship to the first dose of study intervention). * The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. * Capable of giving signed informed consent/assent as which includes compliance with the requirements Randomization inclusion criteria- * Type 2 high disease at risk of asthma exacerbations as defined by either: * An elevated peripheral blood eosinophils (EOS) count of \>=500 cells/milliliter (mL) at screening or \>=500 cells/mL in the last 3 months prior to the screening visit. OR * An elevated peripheral blood EOS count of \>=300 cells/mL at screening OR \>=300 cells/mL in the last 3 months prior to the screening visit AND * Fractional exhaled nitric oxide \>=35 parts per billion (ppb) at screening. OR * Documented current Chronic Rhinosinusitis with Nasal Polyps. Exclusion Criteria: * Participants have had 3 or more exacerbations in the last year prior to Visit 1. * Participants on maintenance OCS or high dose ICS/LABA for asthma. * Participants with a duration of asthma greater than (\>)20 years. * Presence of a known pre-existing, clinically important lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or a history of lung cancer. Participants with current diagnoses of emphysema or chronic bronchitis (Chronic Obstructive Pulmonary Disease other than asthma) are excluded. * Participants with other conditions that could lead to elevated EOS such as hypereosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome) or eosinophilic esophagitis. * Participants who developed an exacerbation within 4 weeks before screening. * Participants with a known, pre-existing parasitic infestation within 6 months prior to screening unless treated and evidenced to have been resolved. * A known immunodeficiency (e.g. human immunodeficiency virus), other than that explained by the use of CS taken as therapy for asthma. * A current malignancy or previous history of cancer in remission for less than 12 months prior to screening. * Participants who have known, pre-existing, clinically significant cardiac, endocrine, autoimmune, metabolic, neurological, psychiatric, renal, gastrointestinal, hepatic, hematologic or any other system abnormalities that are uncontrolled with standard treatment. * Participants with current diagnosis of vasculitis. * Participants who have received treatment with any approved or investigational biologic monoclonal antibody (mAb). * A history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to the first dose of study intervention. * Current smokers or former smokers with a smoking history of \>=20 pack years (number of pack years = \[number of cigarettes per day/20\] \* number of years smoked) and vapers. * Participants with allergy/intolerance to a mAb or biologic or any of the excipients of depemokimab. * Participants who are pregnant or breastfeeding. * Participants who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations. * Evidence of clinically significant abnormality in the hematological, biochemical or urinalysis screen at screening (Visit 0), as judged by the investigator. Liver safety exclusion criteria: * Alanine aminotransferase (ALT) \>2\* Upper limit of normal (ULN). * Total bilirubin \>1.5\*ULN; For participants with Gilbert's syndrome: can be included with total bilirubin \>1.5\*ULN as long as direct bilirubin is less than or equal to (\<=)1.5\*ULN. * Cirrhosis or current unstable liver or biliary disease as per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice. Cardiac safety exclusion criteria: * Electrocardiogram (ECG) Assessment: QTc corrected by Fridericia's formula (QTcF) \>=450 millisecond (msec) or QTcF \>=480 msec for participants with Bundle Branch Block in the 12-lead ECG central over-read from Screening Visit, or in the 12-lead ECG machine read at Visit 1. * Participants are excluded if an abnormal ECG finding from central over read of the 12 lead ECG conducted at Screening Visit is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the investigator. Randomization exclusion criteria: * ECG Assessment: QTcF \>=450 msec or QTcF \>=480 msec for participants with Bundle Branch Block in the 12-lead ECG central over-read from Screening Visit, or in the 12 lead ECG machine read at Visit 1. * ALT \>2\*ULN. * Total bilirubin \>1.5\*ULN; For participants with Gilbert's syndrome can be included with total bilirubin \>1.5\*ULN as long as direct bilirubin is \<=1.5\*ULN. * Participants with a clinically significant asthma exacerbation in the 7 days prior to randomization should have their randomization visit delayed until the investigator considers the participant's asthma to be stable. * Maintenance Asthma Therapy: Any changes in the dose or regimen of baseline ICS and/or addit

Inclusion Criteria: * Aged 50-80 years old * Major Depressive Disorder * Absence or mild cognitive impairment Exclusion Criteria: \-

Inclusion Criteria: 1. 18 years of age or older 2. Diagnosis of breast cancer 3. Treatment plan for curative intent radiation at SSBC 4. Radiation treatment frequency can be daily, every other day, and twice weekly 5. Agreeable to and available for focused chair massages post-radiation treatments during the prescribed treatment period Exclusion Criteria: 1. Patients with recurrent disease (breast cancer) 2. Patients treated palliatively with radiation treatments 3. Inability to read and/or understand English (consent and questionnaires in English) 4. Patients with documented cognitive disorder that limits the ability to independently read, understand, and/or complete the survey measures; i.e. dementia, Alzheimer's 5. Patients with major psychiatric disorders not controlled by medication or other psychiatric treatments

Inclusion Criteria: * Provision of written informed consent; * Aged 18 years or over; * Histopathologically confirmed primary breast cancer; * Ownership of a smartphone and ability to independently operate the intervention system; * Regular use (at least three times per week) of one or more third-party social media platforms (e.g., Weibo, Douyin, or Xiaohongshu); * Clear consciousness, basic reading and writing ability (equivalent to primary education or above), and adequate communication capacity; * An estimated life expectancy of six months or longer, as assessed by the treating physician. Exclusion Criteria: * Diagnosed with cognitive impairment or psychiatric disorders that substantially interfere with assessment or participation; * Pregnancy or lactation; * Presence of other malignant tumours, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix, or severe organic disease (including cardiac, hepatic, or renal insufficiency); * Substance abuse (including alcohol or drug dependence) or current suicidal ideation; * Concurrent participation in other clinical trials or interventional studies that may interfere with outcome evaluation.

HEALTHY PARTICIPANTS: Inclusion Criteria: * Postmenopause (al least 1 year). * Normoweight or overweight/obesity. * No personal history of cancer. * Stable weight over the last 3 months (±5%). * Willing to sign the informed consent and comply with all study procedures. Exclusion Criteria: * Personal history of cancer. * Current weight loss treatment (diet, supplementation, surgery, others...). * Bariatric surgery. * No stable pharmacological treatment for at least 3 months. * Diabetes treatment and hormone replacement therapy. * Relevant functional or structural abnormalities of the gastrointestinal tract, such as malformations, angiodysplasias, active peptic ulcers, chronic inflammatory or malabsorption diseases, hiatal hernia, chronic reflux, etc. * High alcohol intake, more than 14 units per week for women and 20 units per week for men. * Surgical interventions resulting in permanent sequelae of the gastrointestinal tract. * Liver disease, except for non-alcoholic fatty liver disease. * Cognitive and/or psychiatric impairment. * Poor compliance or difficulty following study procedures. BREAST CANCER PARTICIPANTS: Inclusion Criteria: * Postmenopause (at least 1 year). * Normoweight or overweight/obesity. * Luminal subtype breast cancer, stages I-II, who require tumor resection and do not require preoperative treatment. * Willing to sign the informed consent and comply with all study procedures. Exclusion Criteria: * Luminal subtype breast cancer stages over than II or other type of breast cancer. * Require preoperative treatment.

Inclusion Criteria: * BMI between 18,5 and 30,0 kg/m2, * between 18 and 40 years of age, and * be able and willing to provide informed consent. Exclusion Criteria: * have a high risk of suicide, * have a lifetime diagnosis of severe neurological disorder (incl. ADHD), schizophrenia, bipolar disorder, or severe substance abuse, posttraumatic stress disorder, obsessive-compulsive disorder, diabetes, epilepsy, or coronary heart disease * have fulfilled criteria for an eating disorder or somatic symptom disorder within the last 12-months, * take medication (except psychopharmacological medication for MDD or anxiety), patients have to be on stable psychopharmacological medication for at least two months before study participation (minimizing confounding effects) * contraindications for MRI (metal implants or claustrophobia) * for female individuals if they are pregnant or nursing at the time, * impaired movement ability or hearing * impaired, uncorrected vision (need contact lenses) * contraindications for tVNS hearing aids or diseased skin on the right ear.

Inclusion Criteria: * Patients must meet the following criteria for study entry: * Signed Informed Consent Form * Female participants who are at least 18 years of age on the day of signing informed consent * Evaluable or measurable disease per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of \> 12 weeks * Adequate hematologic and organ function within 14 days prior to initiation of study treatment, defined by the following: * Absolute neutrophil count ≥ 1500/μL * Hemoglobin ≥ 9 g/dL * Platelet count ≥ 100,000/μL * Fasting glucose \< 126 mg/dL or \< 7 mmol/L and glycosylated hemoglobin (HbA1C) \< 6.5% or \< 48 mmol/mol * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (\< 3 × ULN if Gilbert's disease) * Serum albumin ≥ 2.5 g/dL or 25 g/L * AST and ALT ≤ 2.5 × ULN with the following exception: * Patients with documented liver metastases: AST and ALT ≤ 5.0 × ULN o ALP ≤ 2.5 × ULN with the following exception: * Participants with documented liver or bone metastases: ALP ≤ 5.0 × ULN o INR \< 1.5 × ULN and aPTT \< 1.5 × ULN * For participants requiring anticoagulation therapy with warfarin or similar agents (such as Vitamin K antagonists), a stable INR between 2 and 3 is required. If anticoagulation is required for a prosthetic heart valve, then stable INR between 2.5 and 3.5 is permitted. * Creatinine clearance ≥ 60 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation. • Participants with controlled HBV infection are allowed if they have: * Normal ALT levels * Positive hepatitis B surface antigen (HbsAg) and negative total hepatitis B core antibody (HbcAb) or positive HbcAb and * HBV DNA ≤ 2000 UI/mL * They are under antiviral treatment following local guidelines. Prophylactic treatment and follow-up must be done by a specialized physician per local SoC. The overall potential benefits associated with study treatment should be deemed to exceed the overall risks by the investigator * Negative hepatitis C virus (HCV) antibody test at screening, or a positive HCV antibody test followed by a negative HCV RNA test at screening * Histologically or cytologically documented adenocarcinoma of the breast that is locally advanced or metastatic, not amenable to surgical or radiation therapy with curative intent * Documented HR-negative tumor in accordance with American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines31, defined as \< 1% of tumor cells staining positive for estrogen receptor (ER) and progesterone receptor (PgR), as per the most recently available local assessment. * Documented HER2-negative tumor in accordance with ASCO/CAP guidelines, defined as a HER2 immunohistochemistry (IHC) score of 0 or 1+ , or an IHC score of 2+ accompanied by a negative fluorescence, chromogenic, or silver in situ hybridization test indicating absence of HER2 gene amplification, or a HER2/CEP17 ratio of \< 2.0, based on the most recently available local assessment. * Have progressed after at least one line of systemic therapy in advanced setting. o Patients who received chemotherapy or antibody-drug conjugate (ADC), either with or without a checkpoint inhibitor treatment, in advanced setting are eligible for enrollment * Consent to provide fresh (preferred) or archival tumor tissue specimen, and freshly collected pretreatment blood sample. It is preferred that the specimen be from the most recently collected and available tumor tissue, and whenever possible, from a metastatic site of disease. Archival tumor tissue is defined as tumor tissue that was collected prior to the participant being (pre)screened for the study, and it can be from either the metastatic disease (preferred) or the primary tumor. See Section 8.2.8 for specimen requirements. * Confirmation of biomarker eligibility: valid results from central testing of tumor tissue documenting the presence of a study-eligible PIK3CA mutation. Eligible PIK3CA mutations are defined as follows (71 PIK3CA mutations): H1047D/I/L/N/P/Q/R/T/Y G1049A/C/D/R/S E545A/D/G/K/L/Q/R/V E453A/D/G/K/Q/V E542A/D/G/K/Q/R/V K111E/N/R Q546E/H/K/L/P/R G106A/D/R/S/V N345D/H/I/K/S/T/Y G118D C420R R88Q M1043I/T/V N1044H/I/K/S/T/Y T1025A/I/S The central test for identification of eligible PIK3CA mutations is the whole exome sequencing performed at Sponsor-designated central testing laboratory. * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a highly effective form of contraceptive method (non-hormonal) with a failure rate of \< 1% per year in combination with use of male condom with spermicide (for male partners), unless male sterilization has been confirmed. Agreement to refrain from donating eggs during the treatment period and for at least 60 days after the last dose of inavolisib and at least 3 months after the last dose of eribulin. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state ( ≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception. Exclusion Criteria: * Patients who meet any of the following criteria will be excluded from study entry: * Pregnancy, lactation, or intention to become pregnant during the study o Women of childbearing potential (including those who have had a tubal ligation) must have a negative pregnancy test result within 14 days prior to initiation of study treatment. * Metaplastic breast cancer * Radiotherapy within 4 weeks before Cycle 1 Day 1 * Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes * Malabsorption syndrome or other condition that would interfere with enteral absorption * Inability or unwillingness to swallow pills * Any history of leptomeningeal disease or carcinomatous meningitis * Known and untreated, or active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Patients with a history of treated CNS metastases are eligible, provided they meet all of the following criteria: * Measurable or evaluable disease (per RECIST v1.1) outside the CNS * No ongoing requirement for corticosteroids as therapy for CNS metastases, with corticosteroids discontinued for ≥ 2 weeks prior to enrollment and no ongoing symptoms attributed to CNS metastases * Radiographic demonstration of improvement upon the completion of CNS-directed therapy and no evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study * The screening CNS radiographic study is ≥ 4 weeks since completion of radiotherapy * No history of intracranial hemorrhage or spinal cord hemorrhage * Pleural effusion, pericardial effusion, or ascites requiring drainage procedures every 14 days or more frequently o Indwelling pleural or abdominal catheters may be allowed, provided the patient has adequately recovered from the procedure, is hemodynamically stable and symptomatically improved. * Symptomatic hypercalcemia requiring continued use of bisphosphonate or denosumab therapy o Bisphosphonate and denosumab therapy for bone metastases or osteopenia/osteoporosis is allowed. * Any active infection that, in the opinion of the investigator, could impact patient safety; or serious infection requiring intravenous (IV) antibiotics within 7 days prior to Day 1 of Cycle 1 * Active infla

Inclusion Criteria: 1. Female patients aged ≥ 18 years and ≤ 70 years. 2. Histopathologically confirmed triple-negative breast cancer: Immunohistochemistry (IHC) shows estrogen receptor (ER) and progesterone receptor (PR) are both negative (i.e., positively stained tumor cells account for \<10% of all tumor cells); IHC shows HER2 negative: test result is 0/1+; if the test result is 2+, in situ hybridization (ISH) must show a HER2/CEP17 ratio \< 2.0 or HER2 gene copy number \< 4. 3. Presence of measurable tumor lesions (meeting RECIST 1.1 criteria). 4. ECOG performance status score of 0-2. 5. Life expectancy of no less than 3 months. 6. Adequate major organ function meeting the following criteria (no blood transfusions, no use of leukocyte- or platelet-raising drugs within 2 weeks prior to screening): (1) Hematology requirements: ANC ≥ 1.5 × 10⁹/L; PLT ≥ 90 × 10⁹/L; Hb ≥ 90 g/L. (2) Biochemistry requirements: TBIL ≤ 1.5 × upper limit of normal (ULN); ALT and AST ≤ 1.5 × ULN; Alkaline phosphatase ≤ 2.5 × ULN; BUN and Cr ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min (by Cockcroft-Gault formula). (3) Thyroid-stimulating hormone (TSH) ≤ ULN (if abnormal, T3 and T4 levels should be checked; patients with normal T3 and T4 levels can be enrolled). (4) Cardiac color Doppler ultrasound and echocardiography: Left ventricular ejection fraction (LVEF) ≥ 50%. (5) 18-lead ECG: Fridericia-corrected QT interval (QTcF) \< 480 ms for females. 7.Women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days before enrollment and voluntarily agree to use adequate contraception during the observation period and for 4 months after the last dose of the study drug. 8.Voluntary participation, signed informed consent, and good compliance. Exclusion Criteria: 1. Concurrently receiving anti-tumor therapy in another clinical trial. 2. Received other anti-tumor therapy within 14 days prior to the first dose. 3. Underwent major surgery unrelated to breast cancer within 4 weeks before enrollment, or has not fully recovered from such surgery. 4. Patients with any active autoimmune disease or a history of autoimmune disease (such as, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood may be included; patients requiring bronchodilators for asthma management cannot be included). 5. Severe cardiac disease or discomfort, including but not limited to: history of heart failure or systolic dysfunction (LVEF \< 50%); high-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate \> 100 bpm, significant ventricular arrhythmias (e.g., ventricular tachycardia), or higher-degree atrioventricular block (i.e., Mobitz II second-degree or third-degree AV block); angina requiring anti-anginal medication; clinically significant valvular heart disease; ECG evidence of transmural myocardial infarction; poorly controlled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg). 6. Patients with congenital or acquired immunodeficiency (e.g., HIV infection). 7. Received a live vaccine within 4 weeks prior to study medication or plans to receive one during the study. 8. Inability to swallow tablets, malabsorption syndrome, or any condition affecting gastrointestinal absorption. 9. Known history of allergy to any component of the study drugs in this protocol. 10. Patients with hypocalcemia. 11. Patients unable to maintain a standing or sitting upright position for 30 minutes. 12. Presence of severe concomitant diseases or other comorbidities that would interfere with the planned treatment, or any other condition deemed by the investigator to make the patient unsuitable for participation in this study.

Inclusion Criteria: o Scheduled neurotoxic treatment in any of the following settings: Taxane cohort * Breast cancer patients planned for either neoadjuvant or adjuvant taxane treatment Oxaliplatin cohort * Rectal cancer patients planned for total neoadjuvant treatment including oxaliplatin * Colorectal cancer patients planned for adjuvant chemotherapy including oxaliplatin, without prior neoadjuvant oxaliplatin treatment * Understand written and oral Swedish. Exclusion Criteria: * Previous neurotoxic chemotherapy\* treatment * Distant metastases * Any psychiatric disorder or health disorder that causes an inability to make an informed consent to participate. * Any manifest clinically significant peripheral neuropathy according to treating physician. * Current lymphoedema in limbs requiring compression therapy. * Ongoing pregnancy. * Planned taxane or oxaliplatin treatment shorter than 8 weeks or longer than 26 weeks * Planned compression or cryotherapy of hands and/or feet during taxane or oxaliplatin * Taxanes (docetaxel, paclitaxel, nabpaclitaxel), platinum components (carboplatin, oxaplatin, cisplatin), vinca-alkaloids (vincristine, vinblastine, vinorelbine, eribulin), bortezomid, thalidomide, antibody drug conjugate including vedotin or emtansine.

Adults aged 65 years or older of any sex, gender and ethnic background who meet the following criteria will be eligible to enroll in the present study: Inclusion Criteria: * scheduled for elective TKA within the next week to two months (can be second knee, but cannot be a revision of the original knee) * self-reported good health, including denial of debilitating illness that may affect participation in or be potentially exacerbated by deep, controlled breathing (i.e., chronic obstructive pulmonary disorder \[COPD\], symptomatic or advanced heart failure, complete heart block, glaucoma, epilepsy) * denial of conditions that alter cortisol release or that require corticosteroid therapy (i.e., Cushing's syndrome, Addison's disease, pituitary tumors, adrenal gland tumors, asthma) * denial of severe psychiatric or cognitive conditions that warrant the need for a durable power of attorney (DPOA) * able to understand written and verbal English. Exclusion Criteria: * currently taking oral, injectable, intranasal, topical, or inhaled corticosteroid medications (i.e., prednisone, hydrocortisone, dexamethasone, methylprednisolone, methylprednisolone acetate, triamcinolone, betamethasone, mometasone, fluticasone, budesonide, clobetasol) * do not have the technology requirements to complete data collection (i.e., participant does not have a smartphone, tablet, laptop, or desktop computer; lack of reliable internet) The following exclusion criteria may affect participants' ability to remain in the study following enrollment: • Development of complications during surgery that require prolonged hospitalization into Postoperative Day (POD) 2 (e.g., postoperative intubation and ventilation requirements, intractable pain, intractable nausea/vomiting, signs of infection or sepsis)

Inclusion Criteria: * Adults (≥18 years) with a diagnosis of mild to moderate bilateral primary open-angle glaucoma (POAG) or open-angle glaucoma (OAG). * On 3 topical glaucoma medications at screening, one of which must be a prostaglandin analog. * Post-DSLT and post-washout, baseline intraocular pressure (IOP) 16-36 mmHg in both eyes. * Best-corrected visual acuity (BCVA) ≥20/60 in both eyes. * Ability and willingness to provide informed consent. Exclusion Criteria: * Ocular hypertension only (no glaucomatous damage). * Inability or medical ineligibility for washout of ocular hypotensive medications. * Prior selective laser trabeculoplasty (SLT) within 12 months of screening. * History of glaucoma surgery (trabeculectomy, tube shunt, minimally invasive glaucoma surgery \[MIGS\] affecting outflow). * Narrow or closed angles with gonioscopy (Shaffer grading ≤2). * Active ocular infection, uveitis, or severe dry eye. * Corneal pathology interfering with IOP measurement. * Advanced glaucoma (threat to fixation). * Known hypersensitivity to Rocklatan, latanoprost, or study medication components. * Pregnancy or lactation.

Inclusion Criteria: * "Adult patients aged ≥ 18 years, treated at the referral center for PH management at the Heart Institute of the University of São Paulo Medical School, with an invasive confirmed diagnosis of PAH (mean pulmonary arterial pressure \[mPAP\] greater than 20 mmHg at rest, pulmonary vascular resistance \[PVR\] equal to or greater than 2 Wood units, and pulmonary capillary wedge pressure \[PCWP\] equal to or less than 15 mmHg), and who have been using Iloprost. Exclusion Criteria: * Patients who are unable to perform the 6-minute walk test (6MWT) or who have experienced gastrointestinal bleeding within the 12 weeks prior to the start of the study will be excluded.

Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * At least 18 years of age at the time of signing the Informed Consent Form (ICF) * Patients with POAG AND \[elevated BP OR hypertension (Average SBP on office BP and Home BP ≥120 mmHg AND/OR Average DBP on office BP and Home BP ≥70 mmHg 26) with or without the use of anti-hypertensive medication\] * Patients without recent changes in medication and glaucoma care within the past four weeks. Exclusion Criteria: * Not able to provide informed consent * SBP and/or DBP are ≥ 150 mmHg and/or ≥ 95 mmHg, respectively, on office BP at screening AND on home BP measurement conducted in the week following screening (to identify White Coat Hypertension) to ensure safety. These patients require referral for early treatment. * Aberrant cardiopulmonary exercise test (CPET) at screening (Life-threatening arrhythmias, ischemia,…) * Unable to perform one or more of the four exercise sessions due to physical and or mental limitations (severe lung disease, musculoskeletal issues, unstable angina,…) * Severe osteoarthritis pending knee replacement surgery (these patients may be unable to perform the IRE (i.e. wall squat exercise) * Unable to communicate in Dutch * Active malignancy * Participation in an interventional Trial with an investigational medicinal product (IMP), exercise intervention or device * Unwillingness to repeat ABPM * Relative contraindications to ABPM: diagnosed atrial fibrillation, nighttime workers, occupational drivers

Inclusion Criteria: * Own a smartphone. * Use social media for \>3 hours/day. * Are aged 12-17 years. * Are experiencing feelings of anxiety or depression. * Have a caregiver who is able and willing to participate in the study alongside them. * Have the ability to communicate in English. * Must sign and date the informed consent form, or provide assent and have a Substitute Decision Maker provide informed consent Exclusion Criteria: * Own a smartphone. * Use their smartphone for \>1 hour/day. * Are accompanying a youth participant enrolled in the study. * Have the ability to communicate in English. * Are willing to sign informed consent forms.

Inclusion Criteria: * Age between 18 and 74 years, inclusive * Diagnosis of treatment-resistant Major Depressive Disorder (MDD), single or recurrent episode, in accordance with DSM-5 diagnostic criteria. * Inadequate response to two or more oral antidepressants during the current depressive episode * Inadequate response to at least one pharmacological combination or augmentation strategy * Ability and willingness to provide written informed consent for participation and data collection Exclusion Criteria: * Presence of any contraindication to esketamine administration according to the approved product label * Current participation in another interventional clinical study involving antidepressant medication * Any medical, psychiatric, or other condition that, in the opinion of the investigator, could: (a) compromise participant safety or well-being, or (b) interfere with, limit, or confound study assessments or outcomes

Inclusion Criteria: 1. Age ≥ 18 years old; 2. Patients diagnosed with HR+/HER2- (as defined by the ASCO/CAP guidelines) advanced breast cancer who were treated in our hospital from March 2022 to March 2025; 3. Received CDK4/6 inhibitors (including but not limited to the four currently marketed ones: palbociclib, abemaciclib, ribociclib, and dalpiciclib) as advanced-stage treatment for at least one cycle; 4. Have complete medical history records, including demographic information, pathological reports, treatment records, laboratory test results, and imaging examination reports, etc. Exclusion Criteria: 1. Incomplete medical history data. 2. Only received CDK4/6 inhibitors monotherapy. 3. Received CDK4/6 inhibitors as neoadjuvant/postoperative adjuvant intensification therapy.

Inclusion Criteria: Individuals are eligible to the study if they are: * 55 years or older * Have at least 2 high blood pressure readings ≥ 130/80 mmHg within one month * Past Medical History of hypertension \> 1 year * Taking at least 1 antihypertensive medication * Independent Activities of Daily Livings (ADL) and instrumental Activities of Daily Livings (iADL) * Have a SmartPhone * Live within the Greater Houston Metropolitan Areas * Able to speak English Exclusion criteria: * Unable to verbalize comprehension of study or impaired cognitive function (e.g. dementia) * Not able to monitor blood pressure at home * Plans to relocate outside Houston within the next year